ABSTRACT
AIM: To investigate the efficacy and safety of paclitaxel albumin assisted platinum chemotherapy in the treatment of recurrent and metastatic cervical cancer based on tumor factors and inflammatory status. METHODS: A total of 100 patients with recurrent and metastatic cervical cancer in our hospital from January 2020 to January 2023 were randomly divided into two groups: 50 patients in the control group were treated with paclitaxel-assisted nedaplatin regimen, and 50 patients in the study group were treated with paclitaxel-assisted nedaplatin regimen. The short-term efficacy, tumor factors, inflammatory factors, relapse-metastasis related indexes, quality of life, functional status and adverse reactions were compared between the two groups. RESULTS: The total remission rate of the study group (72.00%) was higher than that of the control group (48.00%) (P0.05), but the total incidence of adverse reactions (12.00%) was lower than that of the control group (32.00%) (P<0.05). CONCLUSION: Paclitaxel albumin-assisted nedaplatin has a reliable effect in the treatment of recurrent and metastatic cervical cancer, which can further reduce the level of tumor factors, relieve inflammation, and has high safety.
ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of different gemcitabine dosage regimens combined with oxaliplatin in the treatment of recurrent metastatic cholangiocarcinoma.METHODS:A total of 100 patients with recurrent metastatic cholangiocarcinoma were randomly divided into group A(50 cases) and B(50 cases).Group A was given Gemcitabine hydrochloride for injection 1 000 mg/m2,d1.8,for fixed drip time 30 min+Oxaliplatin for injection 130 mg/m2,d1,intravenously.Group B was given gemcitabine 1 000 mg/m2,d1.8,with fixed infusion speed of 10 mg/(m2.min)+ Oxaliplatin for injection (same usage and dosage as group A).A treatment course lasted for 3 weeks,and both groups received 2 courses.Clinical efficacies and toxic reaction of 2 groups were observed,and total survival time,progression-free survival time of 2 groups were followed up for 3 years.RESULTS:Both groups completed at least 2 courses of treatment.The objective remission rate and disease control rate of group B were significantly higher than those of group A;total survival time and progression-free survival time of group B were significantly longer than those of group A.The incidence of Ⅲ-Ⅳ degree thrombocytopenia and leucopenia in group B were significantly higher than group A,with statistical significance(P＜0.05).CONCLUSIONS:Gemcitabine dosage regimen of fixed infusion speed combined with Oxaliplation is better than Gemcitabine dosage regimen of fixed drip time for recurrent metastatic cholangiocarcinoma patients in controlling the disease progression,prolonging the survival time and improving the long-term prognosis,but may increase the risk of blood related ADR.
ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of different gemcitabine dosage regimens combined with oxaliplatin in the treatment of recurrent metastatic cholangiocarcinoma.METHODS:A total of 100 patients with recurrent metastatic cholangiocarcinoma were randomly divided into group A(50 cases) and B(50 cases).Group A was given Gemcitabine hydrochloride for injection 1 000 mg/m2,d1.8,for fixed drip time 30 min+Oxaliplatin for injection 130 mg/m2,d1,intravenously.Group B was given gemcitabine 1 000 mg/m2,d1.8,with fixed infusion speed of 10 mg/(m2.min)+ Oxaliplatin for injection (same usage and dosage as group A).A treatment course lasted for 3 weeks,and both groups received 2 courses.Clinical efficacies and toxic reaction of 2 groups were observed,and total survival time,progression-free survival time of 2 groups were followed up for 3 years.RESULTS:Both groups completed at least 2 courses of treatment.The objective remission rate and disease control rate of group B were significantly higher than those of group A;total survival time and progression-free survival time of group B were significantly longer than those of group A.The incidence of Ⅲ-Ⅳ degree thrombocytopenia and leucopenia in group B were significantly higher than group A,with statistical significance(P＜0.05).CONCLUSIONS:Gemcitabine dosage regimen of fixed infusion speed combined with Oxaliplation is better than Gemcitabine dosage regimen of fixed drip time for recurrent metastatic cholangiocarcinoma patients in controlling the disease progression,prolonging the survival time and improving the long-term prognosis,but may increase the risk of blood related ADR.